Table 2.
Metastatic survival according to age, gender, and tumor characteristics (n = 108)
| Characteristics | Median OS (Months) |
95% CI | 3-year Survival rate | P-value | |
|---|---|---|---|---|---|
| Age | < 60 | 32.0 | 29.7–54.3 | 24.2% | 0.818 |
| ≥60 | 28.0 | 20.1–46.0 | 22.3% | ||
| Gender | Male | 22.8 | 6.2–39.4 | 15.4% | 0.287 |
| Female | 44.9 | 18.9–62.9 | 25.6% | ||
| Primary tumor Grade | G1 | 70.0 | 40.2–98.1 | 21.74% | 0.0028 |
| G2 | 28.0 | 18.7–36.1 | 6.25% | ||
| Hepatic Tumor Number | Single | 44.6 | 23.3–65.9 | 23.5% | 0.000 |
| Multiple | 13.0 | 9.5–16.6 | 5.3% | ||
| Lymph-node meta | Present | 32.0 | 11.3–52.7 | 11.3% | 0.035 |
| Absent | 53.0 | 10.4–75.6 | 23.3% | ||
| Tumor origin | Pancreas | 44.6 | 17.9–71.3 | – | 0.273 |
| GI tract | 22.6 | 12.3–33.0 | – | ||
| Treatment modalitiesa | Local treatment | 60.0 | – | 39.0% | 0.009 |
| Systemic treatment | 13.0 | – | 16.8% | ||
| Combined treatment | 27.0 | – | 25.6% | ||
| Longest hepatic tumor diameter | > 4.5 cm | 32.0 | 12.1–51.8 | 0.343 | |
| ≤4.5 cm | 39.7 | 29.9–71.4 | |||
aThe treatment modality was the treatment dealing with the hepatic metastatic masses